Abstract
TTK spindle assembly checkpoint kinase is an emerging cancer target. This preclinical study explored the antitumor mechanism of TTK inhibitor OSU13 to define a strategy for clinical development. We observed prominent antitumor activity of OSU13 in melanoma, colon and breast cancer cells, organoids derived from patients with melanoma, and mice bearing colon tumors associated with G2 cell cycle arrest, senescence, and apoptosis. OSU13-treated cells displayed DNA damage and micronuclei that triggered the cytosolic DNA-sensing cGAS/STING pathway. STING was required for the induction of several proteins involved in T cell recruitment and activity. Tumors from OSU13-treated mice showed an increased proportion of T and NK cells and evidence of PD-1/PD-L1 immune checkpoint activation. Combining a low-toxicity dose of OSU13 with anti–PD-1 checkpoint blockade resulted in prominent STING- and CD8+ T cell–dependent tumor inhibition and improved survival. These findings provide a rationale for utilizing TTK inhibitors in combination with immunotherapy in STING-proficient tumors.
Authors
Vijaya Bharti, Amrendra Kumar, Yinchong Wang, Nikhil Roychowdhury, Daniel de Lima Bellan, Beimnet B. Kassaye, Reese Watkins, Marina Capece, Catherine G. Chung, Gerard Hilinski, Anna E. Vilgelm
Figure 7
OSU13-treated C57BL/6 mice display no signs of severe toxicities when treated 5 days a week.
